Association of diabetes and obesity with adverse outcomes in HCV patents treated with direct-acting antiviral (DAA)
Latest Information Update: 22 Jul 2020
At a glance
- Drugs Daclatasvir (Primary) ; Dasabuvir/ombitasvir/paritaprevir/ritonavir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2020 New trial record
- 11 Jul 2020 Results published in the Digestive Diseases and Sciences